CL2020003008A1 - Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas - Google Patents

Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas

Info

Publication number
CL2020003008A1
CL2020003008A1 CL2020003008A CL2020003008A CL2020003008A1 CL 2020003008 A1 CL2020003008 A1 CL 2020003008A1 CL 2020003008 A CL2020003008 A CL 2020003008A CL 2020003008 A CL2020003008 A CL 2020003008A CL 2020003008 A1 CL2020003008 A1 CL 2020003008A1
Authority
CL
Chile
Prior art keywords
rur20kd
related compositions
compositions
selective treg
treg stimulator
Prior art date
Application number
CL2020003008A
Other languages
English (en)
Inventor
Peter Benedict Kirk
John L Langowski
Jonathan Zalevsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67002369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020003008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2020003008A1 publication Critical patent/CL2020003008A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación proporciona composiciones de estimulador de Treg selectivo, que incluyen RUR20kD-IL-2 y composiciones relacionadas, y métodos de uso de estas composiciones, por ejemplo, para tratar enfermedades autoinmunitarias y/u otras afecciones que responden al tratamiento que es eficaz para proporcionar un aumento de las cantidades y la activación de los linfocitos T reguladores sobre los linfocitos T efectores.
CL2020003008A 2018-05-21 2020-11-19 Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas CL2020003008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21

Publications (1)

Publication Number Publication Date
CL2020003008A1 true CL2020003008A1 (es) 2021-07-30

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003008A CL2020003008A1 (es) 2018-05-21 2020-11-19 Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas

Country Status (21)

Country Link
US (1) US20210205413A1 (es)
EP (1) EP3796940A1 (es)
JP (3) JP7235772B2 (es)
KR (2) KR102706554B1 (es)
CN (2) CN120131983A (es)
AU (3) AU2019274409B2 (es)
BR (1) BR112020021564A2 (es)
CA (1) CA3100204A1 (es)
CL (1) CL2020003008A1 (es)
CO (1) CO2020014510A2 (es)
CR (1) CR20200546A (es)
DO (1) DOP2020000212A (es)
EA (1) EA202092489A1 (es)
EC (1) ECSP20074392A (es)
IL (2) IL312646A (es)
JO (1) JOP20200290A1 (es)
MX (1) MX2024012807A (es)
PE (1) PE20211307A1 (es)
PH (1) PH12020551976A1 (es)
SG (1) SG11202011242SA (es)
WO (1) WO2019226538A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
WO2021143572A1 (zh) * 2020-01-15 2021-07-22 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
JP2021143142A (ja) * 2020-03-11 2021-09-24 花王株式会社 制御性ｔ細胞誘導剤
WO2021236474A1 (en) * 2020-05-22 2021-11-25 Merck Sharp & Dohme Corp. Novel processes for preparing conjugates of the il-2 protein
CA3192744A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for the sequestration of undesirable anti-peg antibodies in a patient
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
EP4447995A1 (en) 2021-12-14 2024-10-23 Nektar Therapeutics Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions
CN115322260B (zh) * 2022-06-13 2026-02-10 杭州高田生物医药有限公司 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
CN116212040B (zh) * 2023-02-14 2025-11-28 河北菲尼斯生物技术有限公司 一种作为Treg靶向调节剂的PEG修饰IL-2的组合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
JP6911044B2 (ja) 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ

Also Published As

Publication number Publication date
JP7235772B2 (ja) 2023-03-08
SG11202011242SA (en) 2020-12-30
KR102706554B1 (ko) 2024-09-12
ECSP20074392A (es) 2021-03-31
DOP2020000212A (es) 2021-03-15
IL278528A (es) 2021-01-31
IL312646A (en) 2024-07-01
JP2023052053A (ja) 2023-04-11
WO2019226538A1 (en) 2019-11-28
IL278528B1 (en) 2024-06-01
US20210205413A1 (en) 2021-07-08
CN112399859B (zh) 2024-11-29
AU2019274409A1 (en) 2020-11-12
AU2022246440B2 (en) 2024-11-14
IL278528B2 (en) 2024-10-01
CR20200546A (es) 2021-05-18
PH12020551976A1 (en) 2021-09-13
AU2022246440A1 (en) 2022-11-03
KR20210002577A (ko) 2021-01-08
CN112399859A (zh) 2021-02-23
EP3796940A1 (en) 2021-03-31
JP2021523922A (ja) 2021-09-09
JP2024116272A (ja) 2024-08-27
JOP20200290A1 (ar) 2020-11-15
AU2025200920A1 (en) 2025-03-13
BR112020021564A2 (pt) 2021-03-02
AU2019274409B2 (en) 2022-07-14
CN120131983A (zh) 2025-06-13
CO2020014510A2 (es) 2021-03-08
JP7801991B2 (ja) 2026-01-19
PE20211307A1 (es) 2021-07-20
CA3100204A1 (en) 2019-11-28
KR20240137713A (ko) 2024-09-20
MX2024012807A (es) 2024-11-08
EA202092489A1 (ru) 2021-03-16

Similar Documents

Publication Publication Date Title
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
MX2019000965A (es) Composiciones y metodos para inihibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos.
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
NI202000085A (es) Moduladores de la expresión de apol1
ECSP21026021A (es) Moduladores de la expresión de pnpla3
MX2019007784A (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus.
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
CL2020001464A1 (es) Péptidos antimicrobianos y métodos para usarlos.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
MX2020009147A (es) Moduladores de la expresion de irf4.
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2021003136A2 (es) Terapias de combinación
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
MX2020003554A (es) Moduladores de la expresion de enac.
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario
AR120038A1 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
UY36305A (es) Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales.